Stephen Schleicher, MD, MBA, is a practicing oncologist at Tennessee Oncology. After receiving a full academic scholarship to attend Vanderbilt School of Medicine, Dr. Schleicher went on to be one of two McArthur Healthcare Leadership Fellows at Harvard, which included internal medicine residency training at Harvard’s Brigham and Women’s Hospital in combination with an MBA at Harvard Business School.
While in Boston, Dr. Schleicher spent time as a consultant at McKinsey and Company. He completed his oncology fellowship training at Memorial Sloan Kettering in New York where he created a healthcare policy track for fellows.
Dana Cardin, MD, MSCI, is an assistant professor of medicine in the division of hematology/oncology. After receiving her undergraduate degree in biology from the University of North Carolina, Dr. Cardin worked for two years in a translational research lab that used gene targeting techniques to create mouse modeling systems to better understand human disease. After this invaluable research experience, she attended medical school at the University of North Carolina, and went on to match at NYU in Diagnostic Radiology. Dr. Cardin completed her internship in internal medicine at Mt. Sinai Hospital in New York, New York, which subsequently led her to Vanderbilt University Medical Center to complete her residency in internal medicine.
Dr. Cardin specializes in malignancies of the gastrointestinal tract with a research interest in phase I and pancreatic cancer trials. She is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research.
Jill Gilbert, MD, joined the Vanderbilt Oncology Program in 2006 and since then has continued her work in head and neck clinical trial investigation. In 2009 she became the program director of the hematology and oncology fellowship at Vanderbilt where she was selected to participate in the ASCO Leadership Development Program. Dr. Gilbert has chaired the Career Development Subcommittee of the Professional Development Committee and now chairs the Oncology Training Program Committee. She is co-chair of the Pre-ASCO Symposium, which targets medical educator professional development, and has been appointed to the Medical Oncology Subspecialty Board of the American Board of Internal Medicine.
Philip Edward Lammers, MD, MSCI, is a board-certified medical oncologist and hematologist with a strong focus on breast cancer. He is the medical director of clinical oncology research and leads the Clinical Trials Committee at Baptist Cancer Center.
Dr. Lammers is an active member in Baptist’s Mid-South Minority and Underserved National Cancer Institute Community Oncology Research Program (NCORP), a program funded by the NCI that allows Baptist patients access to groundbreaking clinical trials.
Along with the Baptist Medical Group breast surgeons, he helps lead the Multidisciplinary Breast Cancer Clinic at Baptist Cancer Center, a biweekly gathering of surgeons, oncologists, hematologists, nurse navigators, and other oncology care providers who meet to discuss patient cases and recommend the best plan of care for the patient.
Dr. Lammers has secured national grant funding for several projects and has been named to several national cancer committees, including the Southwest Oncology Group Breast Cancer Committee.
Gregg Shepard, MD, is a medical oncologist with Tennessee Oncology, PLLC. He is board certified in medical oncology and hematology. Dr. Shepard received his medical degree from the University of Tennessee, Memphis, and completed his residency and fellowship at Wake Forest University Medical Center.